Fig. 2.
Cultured myeloid Myc5 cells reacquire B-lymphoma markers in vivo.
(A) PCR analysis confirming the presence of VDJ-rearrangement in cultured Myc5 cells (far right lane). In preceding lanes, DNAs from primary Myc5 tumor and murine fibroblasts were used as positive and negative controls, respectively. Migration of the rearranged fragment is indicated by the arrow. (B) FACS of cultured Myc5 cells into B220-positive (R1), F4/80-positive (R3), and doubly positive (R2) populations. As indicated by the arrow, the R3 population was expanded and used for tumor production. (C) Flow cytometric analyses of surface markers on sorted Myc5 cells from the R3 fraction that were expanded in culture (in vitro) and subsequently injected into animals and allowed to form secondary tumors (in vivo). Cells stained with specified antibodies are indicated by black histograms; control unstained cells, with open lines. + and − refer to positive and negative staining, respectively. (D) The left panel depicts the same analyses as in panel C but performed on single cell subclones 5/12 and 5/5 from the R3 fraction. The right panel refers to H&E staining of sections of tumors derived from clones 5/12 and 5/5. Original magnification × 40.